Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Summit takes clinical trial participant search online

Hopes to broaden reach of its Duchenne muscular dystrophy study

Digital pharmaSummit is looking to reach potential clinical trial volunteers online via a new resource on utrophin modulation, whose potential as a treatment for Duchenne muscular dystrophy (DMD) the UK biopharma is investigating.

Utrophintrials.com provides information on utrophin and Summit's utrophin modulator clinical trials, including for its lead candidate the orphan drug ezutromid, which is currently in a phase IIa trial.

Glyn Edwards, Summit's chief executive officer, said: “We recognise the dedication and engagement of the DMD community in the search for solutions for this fatal muscle wasting disease, and with this website, seek to provide this community with access to important information about our utrophin modulator programme and clinical trials.

“We are committed to broadening our relationship with the DMD community as we advance ezutromid and other utrophin modulators, which may have the potential to treat all patients with DMD.”

A progressive muscle wasting disease, DMD affects around 50,000 boys and young men in the developed world and currently has no cure.

If Summit can bring ezutromid to market it will compete with PCT Therapeutics' Translarna, which was recommended by NICE in England and Wales earlier this year, and potentially Santhera Pharmaceuticals' delayed Raxone.

13th September 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics